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related”) included opioids, anticonvulsants, nonsteroidal anti-inﬂ ammatory drugs
(NSAIDs), salicylate analgesics, antimigraine agents, muscle relaxants, corticosteroids, 
benzodiazepines, sedatives/hypnotics, tricyclic antidepressants, serotonin-norepineph-
rine reuptake inhibitors (SNRIs), and selective serotonin reuptake inhibitors (SSRIs). 
Mean annual costs per patient were calculated using third-party payments for Rx drug
claims. RESULTS: A total of 77,124 patients met all study entry criteria. Of these FM 
patients, 40,951 (53.1%) had evidence of receipt of opioids in 2006. Total mean
annual Rx drug costs per patient were $2225.92. FM-related Rx drugs represented 
$912.80 (41.0%) of these costs. Opioids were the most costly drug class, accounting
for $272.79 (29.9%) of FM-related Rx drug costs. The next most costly drug class
was anticonvulsants at $112.90 (12.4%), followed by SNRIs at $105.14 (11.5%) and
SSRIs at $78.53 (8.6%). CONCLUSIONS: Given the widespread use of opioids, their 
lack of efﬁ cacy, and their potential for addiction, reducing opioid use may beneﬁ t
patients and reduce costs. New disease management methods and more effective 
medications to treat FM may assist in achieving this goal.
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THE LONG-TERM COST OF ORTHOPAEDIC SURGERY WITH
RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) IN HAEMOPHILIA 
INHIBITOR PATIENTS
Ericsson Å, Haglund M
Novo Nordisk Scandinavia AB, Malmo, Sweden
OBJECTIVES: To measure the long-term cost consequences of using recombinant 
activated factor VII (rFVIIa) in total hip replacement in haemophilia patients with 
inhibitors in a Swedish setting. Severe haemophilic arthropathy has a negative impact
on health-related quality of life due to recurrent bleeds, chronic pain and signiﬁ cantly 
reduced mobility. Successful Elective Orthopaedic Surgery (EOS) of an affected joint 
can lead to decreased bleed frequency into the new joint, less time spent in hospital, 
relief of chronic pain, and increased mobility and health-related quality of life. 
METHODS: A decision-analytic model was designed to assess cost implications of 
using rFVIIa in haemophilia patients with inhibitors who are candidates for surgery. 
It is based on a consensus protocol from an “Elective Orthopaedic Surgery (EOS)
Expert Group” convened in London in 2006. The model calculates costs of surgery
in a ﬁ ve-year perspective, based on data of bleed reduction of 80–89% in the joint 
during the years after surgery. One-way sensitivity analyses were made, varying patient
weight (55–95 kg), length of stay in hospital (8–16 days), number of physiotherapy 
sessions (6–24), number of bleeds in the affected joint over the past 12 months (6–14),
and bleed reduction assumption (70–90%). A unit cost of SEK 5822/mg for rFVIIa 
was used (USD 1  SEK 7.86). RESULTS: Total hip replacement was cost-saving in
the fourth year after surgery, and in a ﬁ ve-year perspective, savings were SEK1,315,749. 
In the sensitivity analyses, surgery was cost-saving within three to ﬁ ve years. The only
exception was seen in patients who had 6 bleedings or less in the affected joint during 
the year preceding surgery. CONCLUSIONS: In a ﬁ ve-year perspective, total hip
replacement using rFVIIa is cost-saving for haemophilia patients with inhibitors who
had more than six bleedings in the affected joint during the previous year prior to 
surgery.
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ESTIMATE COSTS OF COMORBIDITES IN OVERWEIGHT AND OBESE
MEXICAN CHILDREN AGED BETWEEN FIVE AND ELEVEN YEARS UNTIL 
DEATH
Anaya P, Meléndez G
Fundación Mexicana para la Salud, El Arenal Tepepan, D.F, Mexico
OBJECTIVES: To estimate the economic burden of diabetes, hypercholesterolemia 
and hypertension related to overweight and obesity in Mexican children aged between 
ﬁ ve and eleven years during their life-time. METHODS: A Discrete Event Model was 
designed to calculate prevalence and yearly incidence of diabetes, hypercholesterol-
emia and hypertension and its related costs during the life-time of a children cohort
aged between ﬁ ve and eleven at the start of the simulation. The size of the cohort is 
one of one thousand of the total population reported by the Mexican Population
Council for that age range. Data of risk of dying at each age was obtained from the
same source and a 0.2% was added for each comorbidity. Costs were obtained from 
the Popular Insurance report of 2001. Due to the absence of data related to incidence 
of comorbidities in overweight and obese children, adult data was used but smoothed
by an exponential curve. Probability of becoming overweight and obese was obtained 
from the National Health and Nutrition Survey of 2006. A 3% discount rate was used
for all costs. Results are presented in US dollars with an exchange rate of 13.5 MXN 
pesos for 1 US dollar. RESULTS: Total expenditure in comorbidities for children that 
became obese at any time during simulation was $96,632,485,372, for those who
became overweight was $90,513,280,890 and for those that remain in normal weight 
was $55,650,160,294. CONCLUSIONS: From the results of the model it can be said 
that for the group of children currently aged between 5 and 11 years an extra $ 41 
billion will be spend in comorbidities of those that will become obese and an extra $ 
35 billion for those that will become overweight compared to those that will remain 
in a normal weight.
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VARIABILITY OF FEES IN THE FIELD OF HAEMOGRAMS IN THE
AUSTRIAN CONTRACT PHYSICIANS’ AND INSTITUTES’ SECTOR
Scholler C, Weisser A, Wilbacher I, Endel G
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OBJECTIVES: Contracts with physicians or institutes that perform health care 
services can provide price advantages due to competition. The sickness funds of 
the Austrian Social Security signed different contracts concerning haemograms with
physicians or institutes. Claims data, respectively rendered fees suggest a possible 
savings potential in the fee for service system without reducing the scope of the 
procedures or the frequencies. We analyzed the variety of prices in the ﬁ eld of hae-
mograms including contracted physicians and institutes. This shows variability among
the total amount of reimbursement in the Austrian outpatient sector consisting of 
contracted physicians, institutes, and outpatient clinics of hospitals and ambulatories. 
The outpatient sector is supplied with services by contracted physicians. Approxi-
mately 30% of the Austrian outpatient sector cannot be displayed since no data is
available from outpatient clinics of hospitals. METHODS: Price differences for the 
same or similar procedures performed by different contracted physicians or institutes
are evaluated. Different ﬁ nancial impacts (e.g. focusing on average or lowest value)
are simulated. Values were rounded to two decimal points, however, calculated by 15 
decimal points. The fee equals the division of turnover and frequency. RESULTS:
Services in haemograms were brought into account 103,468,542 times in the year 
2006. Calculating all frequencies with the lowest paid fee (turnover/frequency) for 
each service would lead to a lower ﬁ nancial effort of 82% compared to the current
turnover. Calculating all frequencies with the highest fee for service would lead to a
higher effort of 117% compared to the current turnover. CONCLUSIONS: A current 
savings potential of 117%, contrasting the current fee with the most expensive one,
indicates a well established fee negotiation. However, a savings potential of 82% is
worth being considered for further evaluation and, if necessary, the adjustment of fees 
is advisable.
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ECONOMIC BURDEN OF FIBROMYALGIA COMPARED TO OTHER
CHRONIC CONDITIONS
Blum S, Juday T, Erder MH
Forest Research Institute, Jersey City, NJ, USA
OBJECTIVES: Fibromyalgia is a chronic condition characterized by widespread
pain and decreased physical function. This study compares the economic burden
in patients diagnosed with Fibromyalgia (FM) with that of patients diagnosed 
with Chronic Fatigue Syndrome (CFS) and patients with Major Depressive Disorder
and other Depressive Disorders (DEP). METHODS: Claims data were obtained
from the Thomson/Medstat MarketScan Commercial Claims Database. Study subjects
aged 18 with continuous eligibility were required to have q1 inpatient claim or
q2 outpatient claims during 2006 with ICD-9-CM codes for one of the disease condi-
tions. Patient groups were not mutually exclusive (1.0% of FM patients had CFS and 
10.8% had DEP). Mean annual third-party payer costs/patient were calculated based
on paid claims. Incremental costs relative to FM were generated using generalized 
linear models (family  gamma, link  log), adjusting for age, gender, beneﬁ ciary
status, employment status, insurance plan type, comorbid prevalence of FM, DEP, 
CFS, and other comorbidities. RESULTS: A total of 77,124 FM, 11,672 CFS and 
215,380 DEP patients met all study entry criteria. Total unadjusted costs for FM 
patients ($10,187) were similar to that of DEP patients ($10,416) and greater than 
CFS patients ($8,314). The highest unadjusted cost category for all patients were 
outpatient costs (FM $5594; DEP $4972; CFS $4605), followed by inpatient costs 
(FM $2367; DEP $3136; CFS $2067). Prescription costs (FM $2226; DEP $2308,
CFS $1641) were the lowest cost category. After adjusting for covariates, third-party 
payer costs for FM patients were not signiﬁ cantly different than costs for CFS patients
and were 9% ($984) lower costs for DEP patients. CONCLUSIONS: The costs to 
treat FM patients are high and comparable to that for CFS and DEP, other chronic
diseases with similar symptoms and/or often covered by third-party payers. Early 
diagnosis and use of effective treatments for FM could reduce the economic burden 
on third-party payers.
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OBJECTIVES: Examine the real-world role of duloxetine vs. other treatment for low 
back pain (LBP). METHODS: 500 patients, ages 18–64 years, with 1 LBP diagnosis, 
as speciﬁ ed by HEDIS, and 1 duloxetine prescription within a year after LBP diag-
nosis were identiﬁ ed from a large, privately-insured claims database (5 million lives; 
2004–2006). Patients had continuous eligibility 6 months after their index duloxetine
prescription (study period) and 6 months before their index prescription (baseline
period) and no other duloxetine prescription during the baseline period. Duloxetine-
treated patients were matched to 500 LBP patients (controls) who initiated another
pharmacological or non-invasive LBP treatment in the same month from LBP diagno-
sis as duloxetine was initiated in duloxetine-treated patients. Controls were also
matched using baseline propensity scores of duloxetine treatment, speciﬁ c comorbidi-
ties, LBP diagnostic categories and baseline LBP treatments. Patients with back surgery 
prior to index date were excluded. McNemar tests were used to compare study period 
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LBP treatment rates. Wilcoxon signed-rank tests were used to compare study period 
direct (medical and drug) costs from third-party payer perspective. RESULTS: During
the 6-month study period, duloxetine-treated patients vs. controls had signiﬁ cantly 
lower rates of other pharmacological therapy (34.2% vs. 43.4% narcotic opioids, p
 0.004; 30.4% vs. 43.2% NSAIDs, p  0.001; 17.4% vs. 26.2% muscle relaxants, 
p  0.001; 10.6% vs. 20.4% corticosteroids, p  0.001) and non-invasive therapy
(16.4% vs. 35.6% chiropractic therapy, p  0.001; 13.0% vs. 34.2% physical therapy,
p  0.001). Duloxetine-treated patients were also signiﬁ cantly less likely to have a 
back surgery during the study period compared with controls (0.4% vs. 2.0%, respec-
tively; p  0.021). Average 6-month direct costs were not signiﬁ cantly different
between duloxetine-treated patients and controls ($3554 vs. $3637, respectively). 
CONCLUSIONS: Duloxetine treatment in LBP patients vs. other non-surgical treat-
ment was associated with a lower surgery rate as well as reduced rates of other non-
surgical therapies without signiﬁ cant differences in direct costs.
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OBJECTIVES: Hemophilia is a costly chronic illness. Clotting factor accounts for over 
70% of hemophilia costs. We examined health care utilization, factor use and costs
in people with hemophilia A from six Hemophilia Treatment Centers in seven states.
METHODS: Data were obtained prospectively from interviews and chart reviews with 
329 patients aged 2 to 65 years enrolled in the Hemophilia Utilization Group Study
Part V-A(2005–2007). We analyzed one-year health care utilization (outpatient, emer-
gency room visits, and hospitalization) and total cost of clotting factor dispensed. 
Factor cost was estimated using average sales price from Medicare Part B. We further 
examined the association between these variables and clotting factor infusion strate-
gies (episodic(to treat a bleed) versus prophylactic (administrate multiple times each
week)) in patients with severe hemophilia using Chi-square test for categorical vari-
ables or Wilcoxon rank-sum test for continuous variables. RESULTS: Fifty percent of 
patients were adults; Mean age 9.7 o 4.5 years for children and 33.7 o 12.5 years for 
adults. Two-thirds of patients had severe hemophilia. 97% used clotting factor; 68% 
of severe patients infused prophylactically. 89% reported using health services at least
once: 56% had a comprehensive visit(range:0–3); 31% a clinician visit(range:0–14);
23% saw a physical therapist(range:0–21). 19% had emergency room visits and 15% 
were hospitalized. Mean cost of clotting factor was $208,548(median:$232,831) per
patient-year. In patients with severe hemophilia, average number of hospital days/
patient-year was 8(3 for prophylaxis users versus 13 for episodic treatment users, p
 0.14). Patients with severe hemophilia were less likely to have an emergency room 
visit if they were on prophylaxis(13% vs. 25%, p  0.047). Mean factor cost was
$281,151 per patient-year(median:$224,856) for patients on prophylaxis versus $15
4,855(median:$126,148) for episodic treatment users(p  0.0001). CONCLUSIONS:
This study contributes to the growing evidence that prophylactic infusion of clotting
factors, compared to episodic treatment, may be associated with decreased health care
utilization, including emergency room visits and hospitalizations.
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PROCESS MEASUREMENT AND CALCULATION IN IV-PCA AT
UNIVERSITY HOSPITAL OULU FINLAND
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OBJECTIVES: To describe and measure intravenous patient controlled analgesia (IV-
PCA) processes in postoperative pain management in patients with moderate to severe
pain in clinical practice that have undergone surgery at the University Hospital Oulu
Finland. METHODS: A model was designed and visualized via Swimlane notation. 
Sub process levels were deﬁ ned as “education”, “purchasing/depreciation/mainte-
nance”, “procurement”, “supply”, “application” and “disposal”. Based on these sub
process levels, data was collected by two research methods, interviews and measure-
ment forms including patient and staff satisfaction questionnaires. RESULTS: Twelve
members of Oulu University Hospital personnel with different responsibilities were 
interviewed to deﬁ ne the roles and activities involved in the entire IV-PCA process. 
Ten different roles were deﬁ ned with 151 different activities. The involved roles and
the duration of each activity in the sub process levels “supply”, “application” and
“disposal” were measured from 108 consecutive patients with eight different surgery 
types. The most common surgery types were back surgery and gynecological laparos-
copy. The average duration of IV-PCA use per patient was 41 hours and 39 minutes. 
The staff spent on average 132 minutes in IV-PCA related activities, of which the nurse
spent 91%. The average cost, including material and staff, for 24-hour usage of IV-
PCA was €122. The patients found the IV-PCA system easy to operate but hindered 
them in mobility and they were not able to sleep unhindered. According to the staff 
the IV-PCA system operated error-free and reliably but hindered the mobilization of 
the patient. CONCLUSIONS: IV-PCA involves many different roles and activities and 
intertwined sub processes. Therefore the whole system is complex and resource
demanding. Comparisons of the results from similar studies at other hospitals will be 
very useful when trying to optimize the process.
SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported
Outcomes Studies
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IMPACT OF OBESITY ON HEALTH-RELATED QUALITY OF LIFE IN
PATIENTS WITH ASTHMA IN THE USA
Kwon JW1, Suh K1, Choi IS1, Sohn HS2, Nam EW1, Barone JA1
1Rutgers University, Piscataway, NJ, USA, 2Sook Myung Women’s University, Seoul, South
Korea
OBJECTIVES: To examine the impact of obesity on health-related quality of life
(HRQOL) in patients with asthma. METHODS: The data used for the present study 
was obtained from the 2004–2006 Medical Expenditure Panel Survey (MEPS) data, 
a comprehensive national representative survey of the U.S. non-institutionalized popu-
lation. Individuals were included if they were aged 18–74, self report of diagnosed
with asthma or diagnosed with ICD-9 code of 493 by their physician, and did not 
have pregnancy, malignancy, kidney dialysis, or immunodeﬁ ciency. Asthma patients 
were classiﬁ ed as normal (body mass index(BMI):18.5-25), or obese(BMI:q30). 
MEPS measured HRQOL using SF-12 physical component scale (PCS-12), SF-12
mental component scale (MCS-12), Kessler Index (K-6), and Patient Health Question-
naire (PHQ2). The K-6 assesses the person’s non-speciﬁ c psychological distress (higher 
value means severe mental disability) and the PHQ2 assesses the depression severity.
PHQ2 score of q3 was used to screen asthma patient with depression. The impact of 
obesity on HRQOL was estimated using multivariable regression while controlling for 
patients’ demographic, socio-economic, and co-morbidity variables. Data were ana-
lyzed using SAS and STATA. RESULTS: A total of 5339 asthma patients were identi-
ﬁ ed. Overall, HRQOL in obese patients were signiﬁ cantly lower compared to those 
of normal weight patients (50.7 vs. 41.9 for PCS-12, 49.0 vs. 47.0 for MCS-12, 3.9 
vs. 5.3 for K-6, 0.6 vs. 1.1 for PHQ-2). While controlling for the study variables, QOL
were worse if patients were obese, older, female, or less educated, as well as have car-
diovascular disease. Proportion of patients with PHQ2 score q3 were 10.3% in normal 
weight and 19.7% in obese patients. CONCLUSIONS: Obesity signiﬁ cantly deterio-
rates quality of life including both physical and mental components in asthma patients.
The national health promotion to control weight needs to be emphasized to increase 
the beneﬁ cial effects of HRQL in asthma patients.
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THE RELATIONSHIP BETWEEN QUALITY OF LIFE, DISABILITY AND 
PAIN IN PATIENTS WITH FAILED BACK SURGERY SYNDROME
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OBJECTIVES: Patients with failed back surgery syndrome (FBSS) and chronic neuro-
pathic pain experience levels of health-related quality of life (HRQoL) that are con-
siderably lower than those reported in other areas of chronic pain. Interventions aimed 
at reducing pain in FBSS patients are expected to bring considerable HRQoL improve-
ments. Using data from the multinational PROCESS trial, we investigated the longi-
tudinal relationship between generic HRQoL – assessed using two instruments often 
used in clinical trials (i.e. the SF36 and EuroQol5D) – and disease speciﬁ c outcome
measures (i.e. Oswestry Disability Index [ODI], leg and back pain visual analogue 
scale [VAS]) in neuropathic patients with FBSS. METHODS: Multivariate hierarchical 
regression models to capture the longitudinal trend in the dependent variables (i.e.
generic HRQoL), and to assess their relationship with patient baseline variables and 
clinical history. RESULTS: Generic HRQoL was univariately consistently associated
with disease speciﬁ c outcome measures: ODI (correlation coefﬁ cient: 0.462 to 
0.638) and leg pain VAS (correlation coefﬁ cient: 0.165 to 0.436). In multilevel 
regression analysis, baseline HRQoL and ODI were found to be signiﬁ cant predictors 
of generic HRQoL (all p  0.001). Leg pain was predictive of EuroQol5D and the
SF36 physical component summary score (both p  0.001) but not of its mental com-
ponent summary score (p  0.201). Baseline socio demographic characteristics (age
and gender), clinical history (time since last back surgery and number of back surger-
ies), location of pain and intensity of back pain were not predictive of generic HRQoL
(all p  0.10). CONCLUSIONS: Reduction in leg pain and functional disability is 
statistically signiﬁ cantly associated with improvements in generic HRQoL. This is the 
ﬁ rst study to investigate the longitudinal relationship between generic and disease 
speciﬁ c HRQoL of neuropathic pain patients with FBSS, using multinational data.
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THE HEALTH BURDEN OF NEUROPATHIC PAIN: A SYSTEMATIC REVIEW
AND META-ANALYSIS OF HEALTH UTILITIES
Taylor RS1, Jensen M2, Doth AH3
1Universities of Exeter and Plymouth, Exeter, UK, 2University of Washington School of 
Medicine, Seattle, WA, USA, 3Medtronic Neuromodulation, Minneapolis, MN, USA
Patients with neuropathic pain (NeuP) report poorer health-related quality of life
(HRQoL) and incur higher health care costs than non neuropathic pain patients. 
Although the impact of NeuP on HRQoL has been the subject of previous reviews,
